Schrödinger, Inc. (SDGR)

NASDAQ: SDGR · Real-Time Price · USD
11.52
-0.06 (-0.52%)
At close: Apr 6, 2026, 4:00 PM EDT
11.57
+0.05 (0.43%)
Pre-market: Apr 7, 2026, 5:21 AM EDT
Market Cap850.47M -48.6%
Revenue (ttm)255.87M +23.3%
Net Income-103.27M
EPS-1.41
Shares Out 73.83M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume901,522
Open11.60
Previous Close11.58
Day's Range11.52 - 11.76
52-Week Range10.95 - 27.63
Beta1.62
AnalystsBuy
Price Target21.13 (+83.42%)
Earnings DateMay 6, 2026

About SDGR

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and cli... [Read more]

Sector Healthcare
IPO Date Feb 6, 2020
Employees 850
Stock Exchange NASDAQ
Ticker Symbol SDGR
Full Company Profile

Financial Performance

In 2025, Schrödinger's revenue was $255.87 million, an increase of 23.29% compared to the previous year's $207.54 million. Losses were -$103.27 million, -44.81% less than in 2024.

Financial Statements

Analyst Summary

According to 8 analysts, the average rating for SDGR stock is "Buy." The 12-month stock price target is $21.13, which is an increase of 83.42% from the latest price.

Price Target
$21.13
(83.42% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on March 14, 2026, the company granted (i) a non-statutory stock option to purchase 1,950 shares of the company's common...

Other symbols: SDGR
19 days ago - Business Wire

Schrödinger Reports Fourth Quarter and Full-Year 2025 Financial Results

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced financial results for the fourth quarter and full-year ended December 31, 2025, and provided its 2026 outlook and 2028 finan...

Other symbols: SDGR
5 weeks ago - Business Wire

Schrödinger to Participate in Upcoming Investor Conferences

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in the following conferences in March: TD Cowen 46th Annual Health Care Conference: Firesid...

Other symbols: SDGR
5 weeks ago - Business Wire

Top 3 Health Care stocks That Could Lead To Your Biggest Gains In Q1

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: GMABHSTMSDGR
6 weeks ago - Benzinga

Schrödinger to Announce Fourth Quarter and Full-Year 2025 Financial Results on February 25

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) will report its fourth quarter and full-year 2025 financial results on Wednesday, February 25, 2026, after the financial markets close. The ...

Other symbols: SDGR
7 weeks ago - Business Wire

Schrödinger Provides Update on Progress Across the Business and Outlines 2026 Strategic Priorities

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) provided an update on its progress across the business in 2025 and announced its strategic priorities for 2026. The company is continuing to...

Other symbols: SDGR
3 months ago - Business Wire

Schrodinger to offer Eli Lilly's AI drug discovery platform on its software

Schrodinger said on Friday it is collaborating with Eli Lilly to offer the pharmaceutical major's AI-based platform, TuneLab, on its drug designing software.

Other symbols: LLYSDGR
3 months ago - Reuters

Schrödinger Partners with Lilly to Make TuneLab Platform Available in LiveDesign

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced a collaboration with Lilly TuneLab™, a platform launched by Eli Lilly and Company (Lilly) designed to accelerate drug discov...

Other symbols: SDGR
3 months ago - Business Wire

Schrödinger to Present at Jefferies London Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference. The live presentation wil...

Other symbols: SDGR
5 months ago - Business Wire

Schrödinger Reports Third Quarter 2025 Financial Results

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced financial results for the quarter ended September 30, 2025. "Schrödinger delivered a solid third quarter with software reven...

Other symbols: SDGR
5 months ago - Business Wire

Copernic Catalysts Announces Achievement of Ammonia Catalyst Milestone in Research Collaboration with Schrödinger

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Copernic Catalysts, Inc. (Copernic) today announced that, in collaboration with Schrödinger, Inc. (Nasdaq: SDGR), the companies have surpassed the final technical mi...

Other symbols: SDGR
5 months ago - Business Wire

Schrödinger to Announce Third Quarter 2025 Financial Results on November 5

NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR) will report its third quarter 2025 financial results on Wednesday, November 5, 2025, after the financial markets close. The company will host a co...

Other symbols: SDGR
5 months ago - Business Wire

Schrödinger to Present at Morgan Stanley Global Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference. The live...

Other symbols: SDGR
7 months ago - Business Wire

Schrödinger Announces Discontinuation of SGR-2921 Program

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced the discontinuation of the clinical development program for SGR-2921, its CDC7 inhibitor, which was being evaluated in a Pha...

Other symbols: SDGR
8 months ago - Business Wire

Schrödinger Reports Second Quarter 2025 Financial Results

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced financial results for the quarter ended June 30, 2025.

Other symbols: SDGR
8 months ago - Business Wire

Schrödinger to Announce Second Quarter 2025 Financial Results on August 6

NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR) will report its second quarter 2025 financial results on Wednesday, August 6, 2025, after the financial markets close. The company will host a con...

Other symbols: SDGR
9 months ago - Business Wire

Material Informatics Company Evaluation Report 2025 | Schrodinger, Dassault Systèmes, and Citrine Informatics Drive Market Growth Through AI, Simulation, and Collaboration

The Material Informatics Companies Quadrant presents an in-depth analysis of the global material informatics market. This industry review highlights leading companies, technological advancements, and ...

Other symbols: SDGR
9 months ago - GlobeNewsWire

Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target

NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ajax Therapeutics, Inc. and Schrödinger, Inc. (Nasdaq: SDGR) today announced an expansion of their exclusive research collaboration to include a new Janus...

Other symbols: SDGR
9 months ago - Business Wire

Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that SGR-1505, its clinical stage MALT1 inhibitor, was designated as a Fast Track product by the U.S. Food and Drug Administ...

Other symbols: SDGR
10 months ago - Business Wire

Schrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress

MILAN--(BUSINESS WIRE)--Schrödinger announces encouraging initial clinical data from its ongoing Phase 1 dose-escalation study of SGR-1505.

Other symbols: SDGR
10 months ago - Business Wire

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Shareholders to Inquire about Securities Investigation

NEW YORK, NY / ACCESS Newswire / June 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Schrödinger, Inc. ("Schrödinger" or "the Company") (NASD...

Other symbols: SDGR
10 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Shareholders to Connect

NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Schrödinger, Inc. ("Schrödinger" or "the Company") (NASD...

Other symbols: SDGR
10 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Schrödinger, Inc. (SDGR) And Encourages Shareholders to Reach Out

NEW YORK, NY / ACCESS Newswire / June 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Schrödinger, Inc. ("Schrödinger" or "the Company") (NASD...

Other symbols: SDGR
10 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Shareholders to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / June 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Schrödinger, Inc. ("Schrödinger" or "the Company") (NASD...

Other symbols: SDGR
10 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Stockholders to Inquire about Securities Investigation

NEW YORK, NY / ACCESS Newswire / June 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Schrödinger, Inc. ("Schrödinger" or "the Company") (NASD...

Other symbols: SDGR
11 months ago - Accesswire